UroLift® System
The UroLift® System is a minimally invasive procedure to treat symptoms of an enlarged prostate secondary to benign prostatic hyperplasia (BPH). It is a proven option for patients looking for an alternative to medications or major surgery.*
The UroLift® System is composed of two main components, the UroLift® Delivery Device (single use), and the UroLift® Implants (one implant per delivery device). Each UroLift® Delivery Device comes pre-loaded with one UroLift® Implant.
The UroLift® System (UL-400) are sold packaged in one (1) box containing four (4) individually packaged UroLift® System devices.
*Roehrborn, Can J Urol 2017
As with any medical procedure, individual results may vary. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information.
Warning: This device contains stainless steel and nitinol, an alloy of nickel and titanium. Persons with allergic reactions to these metals may suffer an allergic reaction to this implant. Prior to implantation, patients should be counseled on the materials contained in the device, as well as potential for allergy/hypersensitivity to these materials.
INDICATIONS FOR USE
In the United States, the UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH), including lateral and median lobe hyperplasia, in men 45 years of age or older.
CONTRAINDICATIONS
In the United States, The UroLift® System should not be used if the patient has:
• Prostate volume of >100 cc
• A urinary tract infection
• Urethral conditions that may prevent insertion of delivery system into bladder
• Urinary incontinence due to incompetent sphincter
• Current gross hematuria
MAC02527-16 Rev.A